pha665752 Search Results


94
MedChemExpress met inhibitor pha 665752
Met Inhibitor Pha 665752, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/PHA-665752/bio_rxiv__64898__2026__04__30__721884-47-7-30
Average 94 stars, based on 1 article reviews
met inhibitor pha 665752 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
TargetMol pha 665752
Pha 665752, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/PHA-665752/pmc12572266-37-0-10
Average 94 stars, based on 1 article reviews
pha 665752 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Tocris pha665752
Pha665752, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/PHA+665752/pm21464397-55-8-11
Average 94 stars, based on 1 article reviews
pha665752 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Selleck Chemicals pha665752
Pha665752, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/PHA-665752/10__1158_slash_1078___0432__ccr___14___3319-56-7-13
Average 93 stars, based on 1 article reviews
pha665752 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology pha665752
Pha665752, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/PHA+665752/pmc04679183-74-10-11
Average 93 stars, based on 1 article reviews
pha665752 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Tocris tocris 2693
Tocris 2693, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/PHA+665752/pmc04924710-29-1-1
Average 93 stars, based on 1 article reviews
tocris 2693 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Pfizer Inc pha-665752 ( 13 )
Pha 665752 ( 13 ), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/pha665752/pmc03101852-214-1-10
Average 90 stars, based on 1 article reviews
pha-665752 ( 13 ) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck KGaA pha-665752
Hepatocyte growth factor (HGF) increases gephyrin clustering in vitro . Hippocampal neurons were left untreated or were treated with DMSO, HGF, or <t>PHA-665752.</t> Representative images of gephyrin- or MAP2-stained hippocampal neurons are shown in the absence (A–A”) or presence (B–B”) of HGF. Overview images are shown in ( A,B ; scale bar 20 μm) while insets are enlarged in ( A’,A”,B’,B” ; scale bar 10 μm). Panels (A’,B’) depict confocal images, (A”,B”) processed images for the quantification of gephyrin cluster (red) densities within masks of MAP2-positive dendritic segments (25 μm). ( C) Quantification of gephyrin cluster densities. One-way ANOVA and Tukey’s multiple comparison test F (4,364) = 0.7245. CTR: n = 75, HGF: n = 71, DMSO n = 78, PHA n = 73, PHA/HGF n = 72. *** p < 0.0001, error bars SEM. (D,E) Untreated hippocampal neurons (D) or treated with HGF (E) were stained for phosphorylated p70S6K (pS6K, scale bar 20 μm). Insets are enlarged in ( D’,E’ ; scale bar 10 μm) for determination of mean fluorescence intensities of phosphorylated p70S6K signals within a mask of MAP2-positive cell bodies. Dashed outlines mark the area of the cell bodies. (F) Quantification of phosphorylated p70S6K intensities. CTR n = 57, DMSO n = 83, HGF n = 83, PHA n = 68, PHA/HGF n = 77. One-way ANOVA and Tukey’s multiple comparison test F (4,363) = 3.369. *** p < 0.0001, error bars: SEM.
Pha 665752, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/pha+665752/pmc08155383-38-38-39
Average 90 stars, based on 1 article reviews
pha-665752 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Funakoshi ltd type i met inhibitor pha665752
Hepatocyte growth factor (HGF) increases gephyrin clustering in vitro . Hippocampal neurons were left untreated or were treated with DMSO, HGF, or <t>PHA-665752.</t> Representative images of gephyrin- or MAP2-stained hippocampal neurons are shown in the absence (A–A”) or presence (B–B”) of HGF. Overview images are shown in ( A,B ; scale bar 20 μm) while insets are enlarged in ( A’,A”,B’,B” ; scale bar 10 μm). Panels (A’,B’) depict confocal images, (A”,B”) processed images for the quantification of gephyrin cluster (red) densities within masks of MAP2-positive dendritic segments (25 μm). ( C) Quantification of gephyrin cluster densities. One-way ANOVA and Tukey’s multiple comparison test F (4,364) = 0.7245. CTR: n = 75, HGF: n = 71, DMSO n = 78, PHA n = 73, PHA/HGF n = 72. *** p < 0.0001, error bars SEM. (D,E) Untreated hippocampal neurons (D) or treated with HGF (E) were stained for phosphorylated p70S6K (pS6K, scale bar 20 μm). Insets are enlarged in ( D’,E’ ; scale bar 10 μm) for determination of mean fluorescence intensities of phosphorylated p70S6K signals within a mask of MAP2-positive cell bodies. Dashed outlines mark the area of the cell bodies. (F) Quantification of phosphorylated p70S6K intensities. CTR n = 57, DMSO n = 83, HGF n = 83, PHA n = 68, PHA/HGF n = 77. One-way ANOVA and Tukey’s multiple comparison test F (4,363) = 3.369. *** p < 0.0001, error bars: SEM.
Type I Met Inhibitor Pha665752, supplied by Funakoshi ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/type+i+met+inhibitor+pha665752/pmc08674488-123-17-1
Average 90 stars, based on 1 article reviews
type i met inhibitor pha665752 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Eli Lilly pha665752
Dose–response of U87-H cell line upon treatment with kinase inhibitors or cisplatin. (A) Dose–response of U87-H cells to AG1478, SU1127, or a combination of SU11274 and 5 μM AG1478 over 72 h after 24-h serum starvation. Viability was measured by using the metabolic dye WST-1. Combination treatment significantly enhanced cytotoxicity at 10 μM SU11274 (P < 0.001). (B) Apoptosis measured by caspase 3/7 cleavage upon drug treatment over 24 h after 24-h serum starvation. Concentration of drugs used was 10 μM SU11274, 10 μM AG1478, or a combination of 10 μM SU11274 and 5 μM AG1478. Combination treatment significantly enhanced apoptosis (P < 0.01). (C) Dose–response of U87-H to AG1478, <t>PHA665752,</t> or a combination of PHA665752 and 5 μM AG1478 over 72 h after 24-h serum starvation. Combination treatment significantly enhanced cytotoxicity at 10 μM PHA665752 (P < 0.0001). (D) Viability of U87-H cells in response to a combination treatment of 10 μg/ml cisplatin with either AG1478 or SU11274.
Pha665752, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/pha665752/pmc01937558-272-18-11
Average 90 stars, based on 1 article reviews
pha665752 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Promega met kinase inhibitor pha-665752
Dose–response of U87-H cell line upon treatment with kinase inhibitors or cisplatin. (A) Dose–response of U87-H cells to AG1478, SU1127, or a combination of SU11274 and 5 μM AG1478 over 72 h after 24-h serum starvation. Viability was measured by using the metabolic dye WST-1. Combination treatment significantly enhanced cytotoxicity at 10 μM SU11274 (P < 0.001). (B) Apoptosis measured by caspase 3/7 cleavage upon drug treatment over 24 h after 24-h serum starvation. Concentration of drugs used was 10 μM SU11274, 10 μM AG1478, or a combination of 10 μM SU11274 and 5 μM AG1478. Combination treatment significantly enhanced apoptosis (P < 0.01). (C) Dose–response of U87-H to AG1478, <t>PHA665752,</t> or a combination of PHA665752 and 5 μM AG1478 over 72 h after 24-h serum starvation. Combination treatment significantly enhanced cytotoxicity at 10 μM PHA665752 (P < 0.0001). (D) Viability of U87-H cells in response to a combination treatment of 10 μg/ml cisplatin with either AG1478 or SU11274.
Met Kinase Inhibitor Pha 665752, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/pha+665752/pmc05355264-206-1-8
Average 90 stars, based on 1 article reviews
met kinase inhibitor pha-665752 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ApexBio pha-665752 a2307
Dose–response of U87-H cell line upon treatment with kinase inhibitors or cisplatin. (A) Dose–response of U87-H cells to AG1478, SU1127, or a combination of SU11274 and 5 μM AG1478 over 72 h after 24-h serum starvation. Viability was measured by using the metabolic dye WST-1. Combination treatment significantly enhanced cytotoxicity at 10 μM SU11274 (P < 0.001). (B) Apoptosis measured by caspase 3/7 cleavage upon drug treatment over 24 h after 24-h serum starvation. Concentration of drugs used was 10 μM SU11274, 10 μM AG1478, or a combination of 10 μM SU11274 and 5 μM AG1478. Combination treatment significantly enhanced apoptosis (P < 0.01). (C) Dose–response of U87-H to AG1478, <t>PHA665752,</t> or a combination of PHA665752 and 5 μM AG1478 over 72 h after 24-h serum starvation. Combination treatment significantly enhanced cytotoxicity at 10 μM PHA665752 (P < 0.0001). (D) Viability of U87-H cells in response to a combination treatment of 10 μg/ml cisplatin with either AG1478 or SU11274.
Pha 665752 A2307, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pha665752/specific+hgf+receptor+antagonists++su11274+pha+665752+/pmc10932316-126-0-12
Average 90 stars, based on 1 article reviews
pha-665752 a2307 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Hepatocyte growth factor (HGF) increases gephyrin clustering in vitro . Hippocampal neurons were left untreated or were treated with DMSO, HGF, or PHA-665752. Representative images of gephyrin- or MAP2-stained hippocampal neurons are shown in the absence (A–A”) or presence (B–B”) of HGF. Overview images are shown in ( A,B ; scale bar 20 μm) while insets are enlarged in ( A’,A”,B’,B” ; scale bar 10 μm). Panels (A’,B’) depict confocal images, (A”,B”) processed images for the quantification of gephyrin cluster (red) densities within masks of MAP2-positive dendritic segments (25 μm). ( C) Quantification of gephyrin cluster densities. One-way ANOVA and Tukey’s multiple comparison test F (4,364) = 0.7245. CTR: n = 75, HGF: n = 71, DMSO n = 78, PHA n = 73, PHA/HGF n = 72. *** p < 0.0001, error bars SEM. (D,E) Untreated hippocampal neurons (D) or treated with HGF (E) were stained for phosphorylated p70S6K (pS6K, scale bar 20 μm). Insets are enlarged in ( D’,E’ ; scale bar 10 μm) for determination of mean fluorescence intensities of phosphorylated p70S6K signals within a mask of MAP2-positive cell bodies. Dashed outlines mark the area of the cell bodies. (F) Quantification of phosphorylated p70S6K intensities. CTR n = 57, DMSO n = 83, HGF n = 83, PHA n = 68, PHA/HGF n = 77. One-way ANOVA and Tukey’s multiple comparison test F (4,363) = 3.369. *** p < 0.0001, error bars: SEM.

Journal: Frontiers in Molecular Neuroscience

Article Title: Autism Spectrum Disorder Risk Factor Met Regulates the Organization of Inhibitory Synapses

doi: 10.3389/fnmol.2021.659856

Figure Lengend Snippet: Hepatocyte growth factor (HGF) increases gephyrin clustering in vitro . Hippocampal neurons were left untreated or were treated with DMSO, HGF, or PHA-665752. Representative images of gephyrin- or MAP2-stained hippocampal neurons are shown in the absence (A–A”) or presence (B–B”) of HGF. Overview images are shown in ( A,B ; scale bar 20 μm) while insets are enlarged in ( A’,A”,B’,B” ; scale bar 10 μm). Panels (A’,B’) depict confocal images, (A”,B”) processed images for the quantification of gephyrin cluster (red) densities within masks of MAP2-positive dendritic segments (25 μm). ( C) Quantification of gephyrin cluster densities. One-way ANOVA and Tukey’s multiple comparison test F (4,364) = 0.7245. CTR: n = 75, HGF: n = 71, DMSO n = 78, PHA n = 73, PHA/HGF n = 72. *** p < 0.0001, error bars SEM. (D,E) Untreated hippocampal neurons (D) or treated with HGF (E) were stained for phosphorylated p70S6K (pS6K, scale bar 20 μm). Insets are enlarged in ( D’,E’ ; scale bar 10 μm) for determination of mean fluorescence intensities of phosphorylated p70S6K signals within a mask of MAP2-positive cell bodies. Dashed outlines mark the area of the cell bodies. (F) Quantification of phosphorylated p70S6K intensities. CTR n = 57, DMSO n = 83, HGF n = 83, PHA n = 68, PHA/HGF n = 77. One-way ANOVA and Tukey’s multiple comparison test F (4,363) = 3.369. *** p < 0.0001, error bars: SEM.

Article Snippet: Inhibitors were dissolved in dimethylsulfoxide (DMSO), HGF (Merck KGaA, Darmstadt, Germany) in PBS and added to hippocampal neurons (DIV 9) to final concentrations of 50 ng/ml for HGF, 200 nm for mTOR inhibitor rapamycin (Merck), and 1 μM PHA-665752 (Merck KGaA, Darmstadt, Germany).

Techniques: In Vitro, Staining, Fluorescence

Dose–response of U87-H cell line upon treatment with kinase inhibitors or cisplatin. (A) Dose–response of U87-H cells to AG1478, SU1127, or a combination of SU11274 and 5 μM AG1478 over 72 h after 24-h serum starvation. Viability was measured by using the metabolic dye WST-1. Combination treatment significantly enhanced cytotoxicity at 10 μM SU11274 (P < 0.001). (B) Apoptosis measured by caspase 3/7 cleavage upon drug treatment over 24 h after 24-h serum starvation. Concentration of drugs used was 10 μM SU11274, 10 μM AG1478, or a combination of 10 μM SU11274 and 5 μM AG1478. Combination treatment significantly enhanced apoptosis (P < 0.01). (C) Dose–response of U87-H to AG1478, PHA665752, or a combination of PHA665752 and 5 μM AG1478 over 72 h after 24-h serum starvation. Combination treatment significantly enhanced cytotoxicity at 10 μM PHA665752 (P < 0.0001). (D) Viability of U87-H cells in response to a combination treatment of 10 μg/ml cisplatin with either AG1478 or SU11274.

Journal:

Article Title: Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

doi: 10.1073/pnas.0705158104

Figure Lengend Snippet: Dose–response of U87-H cell line upon treatment with kinase inhibitors or cisplatin. (A) Dose–response of U87-H cells to AG1478, SU1127, or a combination of SU11274 and 5 μM AG1478 over 72 h after 24-h serum starvation. Viability was measured by using the metabolic dye WST-1. Combination treatment significantly enhanced cytotoxicity at 10 μM SU11274 (P < 0.001). (B) Apoptosis measured by caspase 3/7 cleavage upon drug treatment over 24 h after 24-h serum starvation. Concentration of drugs used was 10 μM SU11274, 10 μM AG1478, or a combination of 10 μM SU11274 and 5 μM AG1478. Combination treatment significantly enhanced apoptosis (P < 0.01). (C) Dose–response of U87-H to AG1478, PHA665752, or a combination of PHA665752 and 5 μM AG1478 over 72 h after 24-h serum starvation. Combination treatment significantly enhanced cytotoxicity at 10 μM PHA665752 (P < 0.0001). (D) Viability of U87-H cells in response to a combination treatment of 10 μg/ml cisplatin with either AG1478 or SU11274.

Article Snippet: We thank members of the F.M.W. laboratory for helpful discussions and Eli Lilly for the kind gift of PHA665752.

Techniques: Concentration Assay